The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles

Biomaterials

Volumn 30, Issue 22, 2009, Pages 3645-3651

  Huang, Dong Ming ^a   Hsiao, Jong Kai ^b   Chen, Ying Chun ^a   Chien, Li Ying ^a   Yao, Ming ^c   Chen, Yin Kai ^c   Ko, Bor Sheng ^c   Hsu, Szu Chun ^c   Tai, Lin Ai ^a   Cheng, Hui Ying ^b   Wang, Shih Wei ^d   Yang, Chung Shi ^a   Chen, Yao Chang ^c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Biocompatibility; Cell proliferation; Mesenchymal stem cell; MRI; Nanoparticle

Indexed keywords

CELL CYCLE; CELL-CYCLE PROGRESSION; DELETERIOUS EFFECTS; HUMAN MESENCHYMAL STEM CELLS; HUMAN MESENCHYMAL STEM CELLS (HMSCS); IN-CELL; LYSOSOMAL DEGRADATION; MESENCHYMAL STEM CELL; MRI; STEM CELL; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES;

ANIMAL CELL CULTURE; BIOCOMPATIBILITY; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; GROWTH KINETICS; NANOPARTICLES; SUPERPARAMAGNETISM;

IRON OXIDES;

FERUCARBOTRAN; HYDROGEN PEROXIDE; PEROXIDASE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MESENCHYME CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ANIMALS; CELL CYCLE; CELL PROLIFERATION; CONTRAST MEDIA; FERRIC COMPOUNDS; HUMANS; HYDROGEN PEROXIDE; IRON; MAGNETIC RESONANCE IMAGING; MAGNETICS; MATERIALS TESTING; MESENCHYMAL STEM CELLS; NANOPARTICLES; OXIDANTS; OXIDATION-REDUCTION; OXIDES; PEROXIDASES;

EID: 67349174589     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.03.032     Document Type: Article

References (37)

1. Weissleder R., Cheng H.C., Bogdanova A., and Bogdanova Jr. A. Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging 7 1 (1997) 258-263
2. Bulte J.W., Douglas T., Witwer B., Zhang S.C., Strable E., Lewis B.K., et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 19 12 (2001) 1141-1147
3. Kraitxhman D.L., Heldman A.W., Atalar E., Amado L.C., Martin B.J., Pittenger M.F., et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107 18 (2003) 2290-2293
4. Frank J.A., Zywicke H., Jordan E.K., Mitchell J., Lewis B.K., Miller B., et al. Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol 9 Suppl. 2 (2002) 484-487
5. Arbab A.S., Yocum G.T., Wilson L.B., Parwana A., Jordan E.K., Kalish H., et al. Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. Mol Imaging 3 1 (2004) 24-32
6. Arbab A.S., Yocum G.T., Kalish H., Jordan E.K., Anderson S.A., Khakoo A.Y., et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 104 4 (2004) 1217-1223
7. Hunter A.C. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev 58 14 (2006) 1523-1531
8. Symonds P., Murray J.C., Hunter A.C., Debska G., Szewczyk A., and Moghimi S.M. Low and high molecular weight poly(l-lysine)s/poly(l-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. FEBS Lett 579 27 (2005) 6191-6198
9. Gupta A.K., and Wells S. Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Trans Nanobiol 3 1 (2004) 66-73
10. Gupta A.K., and Gupta M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 26 13 (2005) 1565-1573
11. Hussain S.M., Hess K.L., Gearhart J.M., Geiss K.T., and Schlager J.J. In vitro cytotoxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro 19 7 (2005) 975-983
12. 4 nanoparticles and their biomedical applications. Biomaterials 26 7 (2005) 729-738
13. Petri-Fink A., Chastellain M., Juillerat-Jeanneret L., Ferrari A., and Hofmann A. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials 26 15 (2005) 2685-2694
14. Cengelli F., Maysinger D., Tschudi-Monnet F., Montet X., Corot C., Petri-Fink A., et al. Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J Pharmacol Exp Ther 318 1 (2006) 108-116
15. Kostura L., Kraitchman D.L., Mackay A.M., Pittenger M.F., and Bulte J.W. Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. NMR Biomed 17 7 (2004) 513-517
16. Arbab A.S., Yocum G.T., Rad A.M., Khakoo A.Y., Fellowes V., Read E.J., et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed 18 8 (2005) 553-559
17. Mailänder V., Lorenz M.R., Holzapfel V., Musyanovych A., Fuchs K., Wiesneth M., et al. Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents. Mol Imaging Biol 10 3 (2008) 138-146
18. Gao L., Zhuang J., Nie L., Zhang J., Zhang Y., Gu N., et al. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat Nanotechnol 2 9 (2007) 577-583
19. Arbab A.S., Bashaw L.A., Miller B.R., Jordan E.K., Lewis B.K., Kalish H., et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 229 3 (2003) 838-846
20. Arbab A.S., Wilson L.B., Ashari P., Jordan E.K., Lewis B.K., and Frank J.A. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR Biomed 18 6 (2005) 383-389
21. Burdon R.H. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 18 4 (1995) 948-956
22. Nicco C., Laurent A., Chereau C., Weill B., and Batteux F. Differential modulation of normal and tumor cell proliferation by reactive oxygen species. Biomed Pharmacother 59 4 (2005) 169-174
23. Schreck R., Rieber P., and Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 10 8 (1991) 2247-2258
24. Zhang Y., Zhao W., Zhang H.J., Domann F.E., and Oberley L.W. Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth. Cancer Res 62 4 (2002) 1205-1212
25. 2. Free Radic Biol Med 29 9 (2000) 801-803
26. Lederman H.M., Cohen A., Lee J.W., Freedman M.H., and Gelfand E.W. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 64 3 (1984) 748-753
27. Lucas J.J., Szepesi A., Domenico J., Takase K., Tordai A., Terada N., et al. Effects of iron-depletion on cell cycle progression in normal human T lymphocytes: selective inhibition of the appearance of the cyclin A-associated component of the p33cdk2 kinase. Blood 86 6 (1995) 2268-2280
28. 1 phase of the cell cycle. Cancer Res 53 17 (1993) 3968-3975
29. Gao J., and Richardson D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents: the mechanisms involved in inhibiting cell-cycle progression. Blood 98 3 (2001) 842-850
30. Kulp K.S., Green S.L., and Vulliet P.R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp Cell Res 229 1 (1996) 60-68
31. Simonart T., Degraef C., Andrei G., Mosselmans R., Hermans P., Van Vooren J.P., et al. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J Invest Dermatol 115 5 (2000) 893-900
32. Chaston T.B., Lovejoy D.B., Watts R.N., and Richardson D.R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 9 1 (2003) 402-414
33. Fukuchi K., Tomoyasu S., Watanabe H., Kaetsu S., Tsuruoka N., and Gomi K. Iron deprivation results in an increase in p53 expression. Biol Chem Hoppe-Seyler 376 10 (1995) 627-630
34. Wang G., Miskimins R., and Miskiminis W.K. Mimosine arrests cells in G1 by enhancing the levels of p27(Kip1). Exp Cell Res 254 1 (2000) 64-71
35. Hollstein M., Sidransky D., Vogelstein B., and Harrris C.C. p53 mutations in human cancers. Science 253 5015 (1991) 49-53
36. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 6326 (1991) 453-456
37. Hatakeyman M., and Weiberg R.A. The role of RB in cell cycle control. Prog Cell Cycle Res 1 (1995) 9-19